Danaher Corporation (DHR)
NYSE: DHR · Real-Time Price · USD
244.11
+5.75 (2.41%)
Jan 21, 2025, 4:00 PM EST - Market closed
Danaher Revenue
Danaher had revenue of $5.80B in the quarter ending September 27, 2024, with 3.09% growth. This brings the company's revenue in the last twelve months to $23.74B, up 12.92% year-over-year. In the year 2023, Danaher had annual revenue of $23.89B, down -10.33%.
Revenue (ttm)
$23.74B
Revenue Growth
+12.92%
P/S Ratio
7.56
Revenue / Employee
$376,857
Employees
63,000
Market Cap
176.31B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 23.89B | -2.75B | -10.33% |
| Dec 31, 2022 | 26.64B | 1.84B | 7.42% |
| Dec 31, 2021 | 24.80B | 2.52B | 11.30% |
| Dec 31, 2020 | 22.28B | 4.37B | 24.42% |
| Dec 31, 2019 | 17.91B | 862.00M | 5.06% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.22B |
DHR News
- 16 hours ago - Aldevron Unveils Next-Generation Alchemy™ Cell-Free DNA Technology for Research Grade Applications - Business Wire
- 5 days ago - Danaher: Transition Year Recap - Seeking Alpha
- 5 days ago - The Near-Perfect Dividend Portfolio With 10 Sleep-Well-At-Night Gems - Seeking Alpha
- 6 days ago - Beckman Coulter Introduces Cutting-Edge Research Use Only Assays for Neurodegenerative Disease Research - PRNewsWire
- 7 days ago - Danaher Corporation (DHR) 43rd Annual J.P. Morgan Healthcare Conference (Transcript) - Seeking Alpha
- 8 days ago - Danaher CEO to Comment on Financial Performance - PRNewsWire
- 8 days ago - Using SA's Stock Screener: Sell 6 Overvalued Blue Chips, With Stagnating Growth - Seeking Alpha
- 12 days ago - Danaher Announces Investment Partnership in Innovaccer Inc. - PRNewsWire